Loading…
Medicamen Organics (MEDIORG)₹25.90−2.26%Pharmaceuticals
In the Mar 2026 quarter (consolidated), Medicamen Organics reported sales of ₹4.79 Cr, down 77.9% from Mar 2025, and net profit of −₹6.08 Cr, down 338.4% year on year. For the year to Mar 2026, sales were ₹22.70 Cr and net profit −₹4.03 Cr.
Company filings, consolidated accounts; latest reported quarter Mar 2026
| Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Sales | 14.00 | 16.68 | 21.65 | 17.90 | 4.79 |
| Expenses | 11.61 | 13.85 | 17.70 | 14.42 | 11.93 |
| Operating Profit | 2.32 | 2.72 | 3.84 | 3.41 | −7.15 |
| OPM % | 16.7% | 16.4% | 17.8% | 19.2% | −150.0% |
| Other Income | 0.02 | 0.05 | 0.06 | 0.07 | 0.03 |
| Interest | 0.37 | 0.23 | 0.30 | 0.34 | 0.39 |
| Depreciation | 0.37 | 0.37 | 0.38 | 0.42 | 0.49 |
| Profit before tax | 1.63 | 2.20 | 3.25 | 2.75 | −8.03 |
| Tax % | 22.8% | 30.6% | 21.6% | 25.5% | −24.5% |
| Net Profit | 1.27 | 1.52 | 2.55 | 2.05 | −6.08 |
| EPS (Rs) | 1.46 | 1.28 | 2.16 | 1.73 | −4.96 |
| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| Sales | 25.36 | 38.31 | 22.70 |
| Expenses | 20.52 | 31.53 | 26.35 |
| Operating Profit | 4.73 | 6.60 | −3.74 |
| OPM % | 18.8% | 17.3% | −16.6% |
| Other Income | 1.08 | 0.11 | 0.09 |
| Interest | 0.66 | 0.55 | 0.72 |
| Depreciation | 0.73 | 0.75 | 0.91 |
| Profit before tax | 4.45 | 5.44 | −5.29 |
| Tax % | 40.7% | 25.4% | −23.9% |
| Exceptional items | 1.01 | 0.00 | 0.00 |
| Net Profit | 2.63 | 4.06 | −4.03 |
| EPS (Rs) | 3.04 | 3.45 | −3.29 |
| Dividend payout % | 0.0% | 0.0% | 0.0% |
| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| Equity Capital | 8.60 | 11.71 | 12.18 |
| Reserves | 6.63 | 18.37 | 16.49 |
| Borrowings | 12.64 | 12.34 | 14.28 |
| Other Liabilities | 10.47 | 16.66 | 8.58 |
| Total Liabilities | 38.34 | 59.08 | 51.53 |
| Fixed Assets | 10.34 | 10.12 | 13.36 |
| CWIP | 0.14 | 2.23 | 0.10 |
| Investments | 0.00 | 0.00 | 0.00 |
| Other Assets | 27.86 | 46.73 | 38.07 |
| Inventories | 6.15 | 7.50 | 10.53 |
| Trade receivables | 16.71 | 25.84 | 18.63 |
| Cash & equivalents | 0.54 | 4.12 | 1.29 |
| Total Assets | 38.34 | 59.08 | 51.53 |
| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| Cash from operating activity | −3.65 | −4.53 | −4.59 |
| Cash from investing activity | −0.35 | −2.36 | −1.73 |
| Cash from financing activity | 4.00 | 10.44 | 3.47 |
| Net cash flow | 0.02 | 3.59 | −2.84 |
| Capex | 0.36 | 2.46 | 1.75 |
| Free cash flow | −4.00 | −6.96 | −6.32 |
| CFO / OP % | −72.9% | −66.9% | 119.1% |
| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| Debtor days | 241 | 247 | 300 |
| Inventory days | 243 | 227 | 242 |
| Days payable | 283 | 358 | 130 |
| Cash conversion cycle | 204 | 119 | 415 |
| Working capital days | 73 | 134 | 222 |
| ROCE % | — | 16.9% | −10.6% |
For the Mar 2026 quarter, Medicamen Organics reported sales of ₹4.79 Cr, down 77.9% year on year and net profit of −₹6.08 Cr, down 338.4% year on year. The operating margin was −150.0%.
Medicamen Organics' sales for the year to Mar 2026 were ₹22.70 Cr.
Net profit for the year to Mar 2026 was −₹4.03 Cr. Earnings per share over the same trailing period were ₹−3.29.
Medicamen Organics reported borrowings of ₹14.28 Cr at Mar 2026, against cash and equivalents of ₹1.29 Cr.
Cash from operations was −₹4.59 Cr in the year to Mar 2026; after capital spending, free cash flow was −₹6.32 Cr.